CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Charles River Lbrtrs ntrntl Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Charles River Lbrtrs ntrntl Inc
251 Ballardvale St
Phone: (781) 222-6000p:781 222-6000 WILMINGTON, MA  01887  United States Ticker: CRLCRL
Business Summary
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/30/202312/30/2023YesYes-YesYes

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances
8071 Medical laboratories
8734 Testing laboratories
8999 Services, not elsewhere classified
0252 Chicken eggs
7372 Prepackaged software
8732 Commercial economic, sociological, and educational research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer James C.Foster 72 8/2/2018 1/1/1976
Chief Financial Officer, Corporate Executive Vice President Flavia H.Pease 50 5/1/2022 3/25/2022
Chief Operating Officer, Corporate Executive Vice President BirgitGirshick 53 11/11/2021 2/1/2018
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CHARLES RIVER LABORATORIES EDINBURGH LIMITED ELPHINSTONE RESEARCH CENTRE TRANENT UK
Charles River Laboratories Den Bosch B.V. Hambakenwetering 7 'S-HERTOGENBOSCH NL
Charles River Laboratories SA Netherlands Holding B.V. Hambakenwetering 7 'S-HERTOGENBOSCH Netherlands
28 additional Subsidiary records available in full report.

Business Names
Business Name
Accugenix Inc. LLC
Agilux Laboratories Inc.
Argenta
93 additional Business Names available in full report.

General Information
Number of Employees: 20,000 (As of 12/30/2023)
Outstanding Shares: 51,510,790 (As of 3/15/2024)
Shareholders: 67
Stock Exchange: NYSE
Federal Tax Id: 061397316
Fax Number: (978) 988-5665
Email Address: ir@criver.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024